Publication:
Comparison of cutaneous silent period parameters in patients with primary sjogren's syndrome with the healthy population

Simple item page
dc.contributor.authorKARADAĞ SAYGI, NAİME EVRİM
dc.contributor.authorGÜNDÜZ, OSMAN HAKAN
dc.contributor.authorsYolcu G., Abacar K., Kenis-Coskun O., Inanc N., Karadag-Saygi E., Gunduz O. H.
dc.date.accessioned2022-11-10T11:05:00Z
dc.date.available2022-11-10T11:05:00Z
dc.date.issued2022-06-01
dc.description.abstractBackground: Neurological involvement has a great importance in the clinical spectrum of primary Sjögren’s syndrome (pSS) (1). The presence of small fiber neuropathy (SFN), which cannot be detected in routine electrophysiological examinations, causes the peripheral nervous system involvement to be underestimated in the course of the disease and causes pain-related symptoms in patients that cannot be explained by routine examinations (2). Various methods can be used in the detection of SFN, and cutaneous silent period (CSP) measurement is gaining popularity recently due to its non-invasiveness and practical application (3). Objectives: Evaluating SFN involvement in patients with pSS using CSP and evaluating its relationship with clinical parameters. Methods: Patients with a diagnosis of pSS followed in the rheumatology outpatient clinic and healthy volunteers demographically homogeneous with the patient group were included in the study. The CSP responses were recorded over the abductor pollicis brevis muscle in the upper extremity of all participants. The latency and duration values of the responses were obtained. In patient group, EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), Hospital Anxiety and Depression Scale (HADS), Short Form-36 (SF-36) questionnaire, Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) and Central Sensitization Inventory (CSI) were applied for the evaluation of symptom severity, mood, quality of life, presence of neuropathic pain and central sensitization, respectively. Comparison of CSP parameters between patients with pSS and healthy volunteers was determined as the primary outcome measure. The secondary outcome measure was the relationship between CSP parameters and ESSPRI, HADS, SF-36, LANSS and CSI scores. Results: A total of 36 patients and 36 healthy controls were included in the final analyses. There was no significant difference between the two groups in terms of demographic data. The mean CSP latency was significantly longer in patients with a mean of 78.18 (±7.51) when compared to controls with a mean of 67.91 (±6.41) (95% CI: 6.98- 13.55, p<0.001). Mean CSP duration was also significantly shorter in patients with a mean of 33.40 (±6.93) (95% CI: 9.57 -15.31, p<0.001). There were no significant differences in CSP parameters (latency and duration, respectively) according to patients’ neuropathic pain or central sensitization profile (p>0.05 for all analyses). There were significant correlations of CSP parameters with ESSPRI dryness (r=0.469, p=0.004; r=-0.553, p<0.001), fatigue (r=0.42, p=0.011; r=-0.505, p=0.002), pain (r=0.428, p=0.009; r=-0.57, p<0.001) subscores and mean ESSPRI score (r=0.631, p<0.001; r=-0.749, p<0.001). Significant correlations were not found between CSP parameters and SF-36 scores, other than CSP duration and “pain” subscore (r=-0.395, p=0.017). When the other correlations were investigated there were no significant correlations other than CSP duration and the HADS anxiety score (r=-0.201, p=0.02). Conclusion: As an indicator of CSP measurement, SFN is more common in patients with pSS than in the healthy population. The association with important clinical symptoms of the disease course such as dryness, fatigue, pain and anxiety highlights the importance of detecting small fiber neuropathy
dc.identifier.citationYolcu G., Abacar K., Kenis-Coskun O., Inanc N., Karadag-Saygi E., Gunduz O. H. , "COMPARISON OF CUTANEOUS SILENT PERIOD PARAMETERS IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME WITH THE HEALTHY POPULATION", ANNALS OF THE RHEUMATIC DISEASES, cilt.81, ss.1373-1374, 2022
dc.identifier.doi10.1136/annrheumdis-2022-eular.2052
dc.identifier.endpage1374
dc.identifier.issn0003-4967
dc.identifier.startpage1373
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/91a032b6-f93d-4a3b-b35e-38688693baec/file
dc.identifier.urihttps://hdl.handle.net/11424/283038
dc.identifier.volume81
dc.language.isoeng
dc.relation.ispartofANNALS OF THE RHEUMATIC DISEASES
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectImmunology and Rheumatology
dc.subjectHealth Sciences
dc.subjectROMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectRHEUMATOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectRomatoloji
dc.subjectRheumatology
dc.titleComparison of cutaneous silent period parameters in patients with primary sjogren's syndrome with the healthy population
dc.typearticle
dspace.entity.typePublication
local.avesis.id91a032b6-f93d-4a3b-b35e-38688693baec
local.indexed.atWOS
relation.isAuthorOfPublication5ac4517a-f739-4f83-b6fc-a6f81630bca8
relation.isAuthorOfPublication99eab134-696e-4f08-ad55-8a621e9cc6c2
relation.isAuthorOfPublication.latestForDiscovery5ac4517a-f739-4f83-b6fc-a6f81630bca8

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2.pdf
Size:
356.68 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs